Julie M. Vose

Active 1988–2025

196
Papers
50,751
Citations
110
h-index
193
i10-index

Citations

Citations per year for Julie M. Vose1986: 1 citations1989: 2 citations1990: 1 citations1991: 8 citations1992: 20 citations1993: 28 citations1994: 24 citations1995: 18 citations1996: 22 citations1997: 31 citations1998: 38 citations1999: 35 citations2000: 79 citations2001: 90 citations2002: 132 citations2003: 213 citations2004: 209 citations2005: 297 citations2006: 266 citations2007: 340 citations2008: 332 citations2009: 352 citations2010: 422 citations2011: 503 citations2012: 486 citations2013: 454 citations2014: 439 citations2015: 439 citations2016: 345 citations2017: 370 citations2018: 287 citations2019: 1,209 citations2020: 1,137 citations2021: 1,040 citations2022: 831 citations2023: 681 citations2024: 1,068 citations2025: 458 citations2026: 8 citations1987–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,586 citing papers, 28.4% of this breakdownGermany: 1,108 citing papers, 6.9% of this breakdownUnited Kingdom: 990 citing papers, 6.1% of this breakdownChina: 972 citing papers, 6% of this breakdownFrance: 971 citing papers, 6% of this breakdownItaly: 940 citing papers, 5.8% of this breakdownSpain: 686 citing papers, 4.3% of this breakdownCanada: 647 citing papers, 4% of this breakdownSwitzerland: 496 citing papers, 3.1% of this breakdownJapan: 401 citing papers, 2.5% of this breakdownNetherlands: 385 citing papers, 2.4% of this breakdownAustralia: 380 citing papers, 2.4% of this breakdown
0%28.4%Other 22.1%

Fields

  • Medicine78.8%
  • Biochemistry, Genetics and Molecular Biology13.6%
  • Immunology and Microbiology4.5%
  • Computer Science1%
  • Mathematics0.9%
  • Chemistry0.2%
  • Other1%

Topics

  • Lymphoma Diagnosis and Treatment19%
  • CAR-T cell therapy research6.8%
  • Chronic Lymphocytic Leukemia Research6.3%
  • Viral-associated cancers and disorders5.1%
  • CNS Lymphoma Diagnosis and Treatment4.5%
  • Immune Cell Function and Interaction3.3%
  • Other55%

Coauthors

All papers

Open in search
  1. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando López‐Guillermo, María‐Victoria Mateos, Elizabeth Macintyre, Ari Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano Pileri, Miguel Á. Piris, Barbara Pro, S. Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie H. Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz - Blood 2022 cited by 1,506

  2. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 786

  3. Revised Response Criteria for Malignant Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2007 cited by 4,448

  4. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2015 cited by 1,110

  5. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 176

  6. The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas M. Grogan, Thomas P. Miller, M. Leblanc, German Ott, Stein Kvaløy, Jan Delabie, Harald Holte, Peter Krajči, Trond Stokke, Louis M. Staudt - New England Journal of Medicine 2002 cited by 3,859

  7. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - British Journal of Haematology 2021 cited by 214

  8. Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2024 cited by 139

  9. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laurence de Leval, Joseph M. Connors, Jamés O. Armitage, Julie M. Vose, Wing C. Chan, Louis M. Staudt - Blood 2014 cited by 540

  10. Genomic profiling for clinical decision making in lymphoid neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfgang Hiddemann, Won Seog Kim, Rebecca L. King, Young Hyeh Ko, Ann S. LaCasce, Georg Lenz, José I. Martín‐Subero, Miguel Á. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla‐Martínez, Scott J. Rodig, Andreas Rosenwald, Gilles Salles, Jesús F. San Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier Luigi Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott - Blood 2022 cited by 161

  11. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results

    Authors: , , , , , , , , , , , , , , , , - Blood 2021 cited by 218

  12. Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Masao Seto, Andreas Rosenwald, German Ott, Elı́as Campo, Lisa M. Rimsza, Elaine S. Jaffe, Rita M. Braziel, Francesco d’Amore, Giorgio Inghirami, Francesco Bertoni, Laurence de Leval, Philippe Gaulard, Louis M. Staudt, Timothy W. McKeithan, Stefano Pileri, Wing C. Chan, Javeed Iqbal - Blood 2019 cited by 275

  13. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph M. Tuscano, Julie M. Vose, Mary A. Dwyer, Hema Sundar - Journal of the National Comprehensive Cancer Network 2023 cited by 117

  14. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 1999 cited by 3,490

  15. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nishitha Reddy, Shaoying Li, Caitlin E. Handler, Christopher R. Flowers, Jonathon B. Cohen, Kristie A. Blum, Kevin Song, Haowei Sun, Oliver W. Press, Ryan D. Cassaday, Jesse Jaso, L. Jeffrey Medeiros, Aliyah R. Sohani, Jeremy S. Abramson - Blood 2014 cited by 466

  16. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kapil N. Bhalla, Javeed Iqbal, Timothy C. Greiner, Scott J. Rodig, Adnan Mansoor, Michael R. Green - Haematologica 2021 cited by 74

  17. Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2020 cited by 93

  18. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew A. Lunning, Saurabh Dahiya - Journal of Clinical Oncology 2024 cited by 73

  19. Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Emilio Montserrat, Wyndham H. Wilson, Elaine S. Jaffe, Richard H. Simon, Liming Yang, John Powell, Hong Zhao, Neta Goldschmidt, Michael Chiorazzi, Louis M. Staudt - New England Journal of Medicine 2004 cited by 1,433

  20. IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2015 cited by 248

  21. Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms After Autologous Transplant for Hodgkin Lymphoma

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2024 cited by 27

  22. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

    Authors: , , , , , , , , , , , , , , , - Blood 2017 cited by 320

  23. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

    Authors: , , , , , , , , , , , , , , , , - Blood 2018 cited by 253

  24. Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma

    Authors: , - Blood 2017 cited by 210